Fedratinib in Combination With Nivolumab
A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment
|Condition or Disease||Intervention/Treatment||Phase|
The FRACTION trial will evaluate the clinical efficacy of Fedratinib and Nivolumab combination therapy in patients with primary and secondary myelofibrosis based on the consensus criteria of the International Working Group for Myelofibrosis Research and treatment (IWG-MRT), extended by the criterion RBC-transfusion independence (RBC-TI).
Arms and Interventions
Fedratinib (Cycle 1: Run-in-Phase with 400 mg QD for 4 weeks, Cycle 2-12: 400 mg QD, Dose modifications will be allowed based on observed toxicity to a 300 mg or a 200 mg daily dose) + Nivolumab (Cycle 2-12: 240 mg, i.v., q2w) Patients will receive study treatment until loss of response, death or study discontinuation for other reasons.
Drug: Fedratinib Oral Capsule [Inrebic]
400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
240 mg every 2 weeks i.v. from cycle 2-n
Primary Outcome Measures
- Best response rate within 12 treatment cycles [12 months after therapy start.]
Best response rate within 12 treatment cycles according to the IWG-MRT criteria (including complete remission, CR, partial remission, PR, clinical improvement, CI, stable disease, SD 1, and red cell transfusion (RCT) independency according to Gale et al.)
Secondary Outcome Measures
- Safety: Incidence and severity of adverse events according to CTC criteria [From informed consent until 100 days after last study drug]
Incidence and severity of adverse events according to CTC criteria
- Safety: Timing of adverse events according to CTC criteria [From informed consent until 100 days after last study drug]
Timing of adverse events according to CTC criteria
- Safety: Incidence of Laboratory abnormalities [From informed consent until 100 days after last study drug]
Incidence of laboratory abnormalities including timing and relatedness.
- Safety: leukemic transformation [From informed consent until 100 days after last study drug]
Cumulative incidence of leukemic transformation
- Clinical benefit [3.5 years]
Proportion of patients with clinical benefit defined as stable disease (SD) plus hematologic improvement or stable disease (SD) plus improvement of MF-associated symptoms
- Efficacy: PFS [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months]
- Efficacy: Duration of response [3.5 years]
Time from first response including RBC-TI, CI, PR and CR (Appendix III) to date of loss of response. Times of patients without loss of response are censored at last tumor assessment.
- Efficacy: Overall survival [3.5 years]
Time from study entry to the last date known to be alive or death. Survival times of patients alive at last follow-up are censored.
- Efficacy: Disease burden [3.5 years]
Change of disease burden assessed by allelic ratio of the respective driver mutation and of high-risk mutations by next-generation sequencing [NGS]
Signed Informed Consent Form available and patient willing and able to adhere to the study visit schedule and other protocol requirements.
Patients* ≥18 years of age
diagnosed with myelofibrosis (MF) according to the WHO 2008 or 2016 criteria, including primary (pre-fibrotic or overt) and secondary myelofibrosis.
Patients with an indication for therapy (either symptomatic patients with splenomegaly
11cm diameter and/or symptoms restricting their daily activity or patients with DIPSS int-2, or high risk or MIPSS70 int or high)
- Patients with no response or suboptimal response to any JAK-inhibitor therapy (regarding persistence of symptoms, splenomegaly, cytopenia or hyperproliferation) defined either by
Persisting Splenomegaly >11cm total diameter
Anemia <6.2 mmol/l (<10g/dl)
Elevated WBC (>11 Gpt/l)
Persisting general or constitutional symptoms (persistence is defined as less than 50% reduction to baseline when using the MPN10 TSS Score) OR failure [secondary resistance] to JAK-inhibitor treatment as defined by IWG-MRT criteria.
ECOG performance status <3 at screening and adequate organ function
Reliable contraception should be maintained throughout the study and for 1 month after discontinuation of Fedratinib or 5 months after discontinuation of Nivolumab**
Subject must be willing to receive transfusion of blood products
Thiamine levels within the normal range (prior substitution is possible)
Normal nutritional status
Females of childbearing potential (FCBP) must undergo repetitive pregnancy testing (serum or urine) and pregnancy results must be negative.
Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods (i.e. failure rate of < 1% per year).
Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with FCBP. Males must agree not to donate semen or sperm.
Planned hematopoietic stem cell transplantation within 3 months and suitable donor available
10% blasts in bone marrow smear (cytology) or >2x in blood smear within the screening phase or >20% blasts at any time in bone marrow or peripheral blood smears
Creatinine >2xULN and Creatinine-Clearance <45ml/min; ALAT, ASAT & bilirubin >3xULN (if MF impact on liver >5xULN)
Baseline platelets count below 50 x 109/L and ANC < 1.0 x 109/L
Diagnosis of PV, ET (according to WHO 2016) or positive molecular test for BCR-ABL
Patients on ongoing medication for myelofibrosis including systemic corticosteroids (detailed list of permitted medications is provided in paragraph 22.214.171.124 and Appendix
Evidence of acute or chronic infection with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or tuberculosis
Current participation in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the study, unless it is an observational (non-interventional) study, or during the follow-up period of an interventional study with last dose of investigational product ≥30 days prior first administration of investigational product within this study.
No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation
No consent for biobanking of patient's biological specimens
Prior therapy with checkpoint-inhibitors
Vaccination within 4 weeks prior to treatment start
Hypersensitivity to the IMPs or to any of the excipients
History of or uncontrolled autoimmune disease such as autoimmune-hepatitis, -pneumonitis, -thyroiditis, chronic inflammatory bowel disease, multiple sclerosis, or rheumatologic diseases (including but not limited to systemic lupus and vasculitis)
History of malignancy except for i) adequately treated local basal cell or squamous cell carcinoma of the skin, ii) asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to randomization, or iii) any other cancer that has been in complete remission for ≥ 5 years
Secondary malignancy that limits survival to less than 6 months.
Drug or alcohol abuse within the last 6 months
Patients who cannot adhere to the Pregnancy Prevention Plan
Pregnant or breast-feeding females
Thiamine levels below normal limit despite supplementation
Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]
Contacts and Locations
|1||University Medicine Greifswald||Greifswald||Germany|
|2||Universitätsklinikum Halle (Saale)||Halle (Saale)||Germany|
Sponsors and Collaborators
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Prof. F. Heidel, University Medicine Greifswald
- Celgene International II S.á.r.l.
- Study Director: Salah-Eddin Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
Study Documents (Full-Text)None provided.